PE20121476A1 - Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r - Google Patents

Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r

Info

Publication number
PE20121476A1
PE20121476A1 PE2012000667A PE2012000667A PE20121476A1 PE 20121476 A1 PE20121476 A1 PE 20121476A1 PE 2012000667 A PE2012000667 A PE 2012000667A PE 2012000667 A PE2012000667 A PE 2012000667A PE 20121476 A1 PE20121476 A1 PE 20121476A1
Authority
PE
Peru
Prior art keywords
ddr1
ddr2
bcr
abl
pdgf
Prior art date
Application number
PE2012000667A
Other languages
English (en)
Inventor
Neil Gallagher
Ophelia Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121476(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20121476A1 publication Critical patent/PE20121476A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE PY ES 3-PIRIDILO; R1 ES H, ALQUILO INFERIOR, ALCOXILO INFERIOR-ALQUILO, ENTRE OTROS; R2 ES H, ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO, CICLOALQUILO, BENZO-CICLOALQUILO, ENTRE OTROS; R4 ES H, ALQUILO INFERIOR O HALOGENO. ES COMPUESTO PREFERIDO: 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS O CONDICIONES PATOLOGICAS MEDIADAS POR LA ACTIVIDAD CINASA DE Bcr-Abl, c-KIT, DDR1, DDR2 O PDGF-R
PE2012000667A 2009-11-17 2010-11-17 Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r PE20121476A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26181209P 2009-11-17 2009-11-17

Publications (1)

Publication Number Publication Date
PE20121476A1 true PE20121476A1 (es) 2012-11-14

Family

ID=43513643

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000667A PE20121476A1 (es) 2009-11-17 2010-11-17 Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r

Country Status (37)

Country Link
US (1) US9061029B2 (es)
EP (1) EP2501384B2 (es)
JP (2) JP5829615B2 (es)
KR (1) KR101743315B1 (es)
CN (1) CN102612368B (es)
AR (1) AR079029A1 (es)
AU (1) AU2010322102B2 (es)
BR (1) BR112012011693A2 (es)
CA (1) CA2779490C (es)
CL (1) CL2012001270A1 (es)
CO (1) CO6551690A2 (es)
DK (1) DK2501384T4 (es)
EC (1) ECSP12011903A (es)
ES (1) ES2572128T3 (es)
FI (1) FI2501384T4 (es)
GT (1) GT201200150A (es)
HK (1) HK1169950A1 (es)
HR (1) HRP20160472T4 (es)
HU (1) HUE027307T2 (es)
IL (1) IL219727A (es)
JO (1) JO3634B1 (es)
MA (1) MA33738B1 (es)
ME (1) ME02413B (es)
MX (1) MX2012005694A (es)
MY (1) MY169956A (es)
NZ (1) NZ599968A (es)
PE (1) PE20121476A1 (es)
PL (1) PL2501384T5 (es)
RS (1) RS54747B2 (es)
RU (1) RU2625835C2 (es)
SG (1) SG10201501169VA (es)
SI (1) SI2501384T2 (es)
SM (1) SMT201600143B (es)
TN (1) TN2012000206A1 (es)
TW (1) TWI498116B (es)
WO (1) WO2011062927A1 (es)
ZA (1) ZA201203328B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776130A1 (en) 2011-11-07 2014-09-17 Institut National de la Sante et de la Recherche Medicale (INSERM) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
WO2013161853A1 (ja) * 2012-04-24 2013-10-31 中外製薬株式会社 キナゾリンジオン誘導体
TW201348187A (zh) 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 苯甲醯胺衍生物
AU2013256227B2 (en) * 2012-05-02 2017-06-15 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EA024391B1 (ru) * 2012-05-15 2016-09-30 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
KR20180043199A (ko) * 2015-08-31 2018-04-27 도레이 카부시키가이샤 요소 유도체 및 그 용도
CN108103186B (zh) * 2018-02-28 2021-07-02 固安博健生物技术有限公司 诊断类风湿性关节炎和骨关节炎的分子标志物
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. SALTS OF KINASE INHIBITORS AND ASSOCIATED COMPOSITIONS
WO2020144649A1 (en) * 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4552650B2 (ja) 2002-06-28 2010-09-29 日本新薬株式会社 アミド誘導体及び医薬
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004012662A2 (en) 2002-08-01 2004-02-12 Aesgen, Inc. Improved treatment of cancer with glutamine
BRPI0609296A2 (pt) 2005-05-02 2010-03-23 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistÊmica
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
KR100925559B1 (ko) 2007-10-26 2009-11-05 한국과학기술연구원 악티노마이신 ｄ를 유효성분으로 하는 ｄｄｒ과 콜라겐결합 저해제

Also Published As

Publication number Publication date
CA2779490C (en) 2019-02-12
US20120289528A1 (en) 2012-11-15
PL2501384T5 (pl) 2024-01-29
ME02413B (me) 2016-09-20
JP2013511524A (ja) 2013-04-04
SI2501384T2 (sl) 2024-02-29
CN102612368A (zh) 2012-07-25
GT201200150A (es) 2014-08-11
WO2011062927A1 (en) 2011-05-26
TWI498116B (zh) 2015-09-01
AU2010322102B2 (en) 2014-08-28
CL2012001270A1 (es) 2012-10-12
MY169956A (en) 2019-06-19
NZ599968A (en) 2014-09-26
TN2012000206A1 (en) 2013-12-12
ZA201203328B (en) 2013-02-27
HUE027307T2 (hu) 2016-10-28
ECSP12011903A (es) 2012-09-28
DK2501384T4 (da) 2024-01-02
RU2625835C2 (ru) 2017-07-19
DK2501384T3 (en) 2016-05-17
FI2501384T4 (fi) 2024-01-11
MX2012005694A (es) 2012-06-13
SI2501384T1 (sl) 2016-06-30
JP5829615B2 (ja) 2015-12-09
PL2501384T3 (pl) 2016-08-31
CN102612368B (zh) 2014-03-05
HRP20160472T1 (hr) 2016-06-03
US9061029B2 (en) 2015-06-23
RS54747B1 (sr) 2016-10-31
KR101743315B1 (ko) 2017-06-15
IL219727A0 (en) 2012-07-31
KR20120102635A (ko) 2012-09-18
AU2010322102A1 (en) 2012-05-24
ES2572128T3 (es) 2016-05-30
JO3634B1 (ar) 2020-08-27
EP2501384B2 (en) 2023-11-01
HK1169950A1 (zh) 2013-02-15
SMT201600143B (it) 2016-07-01
MA33738B1 (fr) 2012-11-01
TW201141481A (en) 2011-12-01
CA2779490A1 (en) 2011-05-26
EP2501384A1 (en) 2012-09-26
CO6551690A2 (es) 2012-10-31
SG10201501169VA (en) 2015-04-29
HRP20160472T4 (hr) 2024-02-02
RS54747B2 (sr) 2024-02-29
EP2501384B1 (en) 2016-02-17
AR079029A1 (es) 2011-12-21
BR112012011693A2 (pt) 2016-03-01
RU2012124811A (ru) 2013-12-27
JP2015180636A (ja) 2015-10-15
IL219727A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
CO6801777A2 (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
PE20090717A1 (es) Derivados de quinolina como inhibidores de la pi3 quinasa
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
MX2018013235A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
PE20091324A1 (es) Compuestos espiro como antagonistas del receptor npy y5
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
BRPI0507464A (pt) formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
SI2632921T1 (sl) Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
NZ705144A (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
RU2018119102A (ru) Терапевтическое средство для лечения рака молочной железы

Legal Events

Date Code Title Description
FC Refusal